JP2005512507A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512507A5
JP2005512507A5 JP2002588923A JP2002588923A JP2005512507A5 JP 2005512507 A5 JP2005512507 A5 JP 2005512507A5 JP 2002588923 A JP2002588923 A JP 2002588923A JP 2002588923 A JP2002588923 A JP 2002588923A JP 2005512507 A5 JP2005512507 A5 JP 2005512507A5
Authority
JP
Japan
Prior art keywords
box
biologically active
hmg
active fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002588923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512507A (ja
JP2005512507A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015329 external-priority patent/WO2002092004A2/en
Publication of JP2005512507A publication Critical patent/JP2005512507A/ja
Publication of JP2005512507A6 publication Critical patent/JP2005512507A6/ja
Publication of JP2005512507A5 publication Critical patent/JP2005512507A5/ja
Pending legal-status Critical Current

Links

JP2002588923A 2001-05-15 2002-05-15 抗炎症剤としてのｈｍｇフラグメントの使用 Pending JP2005512507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29103401P 2001-05-15 2001-05-15
US60/291,034 2001-05-15
PCT/US2002/015329 WO2002092004A2 (en) 2001-05-15 2002-05-15 Use of hmg fragment as anti-inflammatory agents

Publications (3)

Publication Number Publication Date
JP2005512507A JP2005512507A (ja) 2005-05-12
JP2005512507A6 JP2005512507A6 (ja) 2005-08-04
JP2005512507A5 true JP2005512507A5 (https=) 2007-08-02

Family

ID=23118552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002588923A Pending JP2005512507A (ja) 2001-05-15 2002-05-15 抗炎症剤としてのｈｍｇフラグメントの使用

Country Status (18)

Country Link
US (2) US20030060410A1 (https=)
EP (1) EP1392844A4 (https=)
JP (1) JP2005512507A (https=)
KR (1) KR20040018370A (https=)
CN (1) CN100447154C (https=)
AU (1) AU2002309829B2 (https=)
BR (1) BR0209689A (https=)
CA (1) CA2447576C (https=)
CZ (1) CZ20033402A3 (https=)
HU (1) HUP0500042A3 (https=)
IL (3) IL158643A0 (https=)
IS (1) IS7037A (https=)
MX (1) MXPA03010449A (https=)
NO (1) NO20035087L (https=)
NZ (1) NZ529423A (https=)
PL (1) PL367132A1 (https=)
SK (1) SK15422003A3 (https=)
WO (1) WO2002092004A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
US20060121047A1 (en) * 2002-11-20 2006-06-08 Tracey Kevin J Use of hmgb polypetides for increasing immune responses
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20040156851A1 (en) * 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US20090069227A9 (en) * 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
JP5622351B2 (ja) * 2004-09-03 2014-11-12 クレアビリス・セラピューティクス・エスピーエー プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
EP1899376A2 (en) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
JP3876325B1 (ja) 2005-10-24 2007-01-31 国立大学法人 岡山大学 脳梗塞抑制剤
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2007102410A1 (ja) * 2006-02-24 2007-09-13 National University Corporation Kanazawa University Rageポリペプチドの新規用途
JP3882090B1 (ja) 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
BRPI0718491A2 (pt) * 2006-09-15 2013-12-03 Creabilis Therapeutics Spa Conjugados poliméricos do box-a da hmgb1 e variantes do box-a da hmbg1
US20100216977A1 (en) * 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
JP5225109B2 (ja) * 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5467313B2 (ja) 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
EP2613797B1 (en) * 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9688733B2 (en) * 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) * 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CN113203857B (zh) * 2021-05-06 2021-12-31 上海奕检医学检验实验室有限公司 一种肿瘤诊断试剂盒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53841A (en) * 1866-04-10 Improvement in measuring-funnels
US60410A (en) * 1866-12-11 newman
US144201A (en) * 1873-11-04 Improvement in volute springs
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
DE69737870T2 (de) * 1996-07-17 2008-02-07 Kaneka Corp. Medikamente für die diagnostik von autoimmunerkrankungen
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US20030027260A1 (en) * 1997-10-17 2003-02-06 Genentech, Inc. Human Toll homologues
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US20030032674A1 (en) * 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
JP2003052763A (ja) * 2001-08-16 2003-02-25 Paramount Bed Co Ltd ベッドにおける側柵

Similar Documents

Publication Publication Date Title
JP2005512507A5 (https=)
JP2006510619A5 (https=)
AP690A (en) Immunomodulators based on a polypeptide other than human interleukin 10.
DK2330129T3 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
EP1313769B2 (en) Antibodies to human il-1 beta
JP2003507364A5 (https=)
JP2009539349A5 (https=)
JP2012087144A (ja) ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体
HRP20180941T1 (hr) Protutijela protiv il-17
JP2023081303A5 (https=)
EP1644416A2 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO1991002078A1 (en) Tumour necrosis factor binding ligands
EP1799260A2 (en) Anti- amyloid antibodies, compositions, methods and uses
SK1152003A3 (en) Dual specificity antibodies and methods of making and using
JP2012504602A5 (https=)
US20140178389A1 (en) Il-1 binding proteins
KR19990077344A (ko) 합성 il-10 동족체
JP2005516606A5 (https=)
JP2005502319A5 (https=)
CA2090401A1 (en) Method of treating viral infection
US5506340A (en) Tumor necrosis factor inhibitors
US20070042963A1 (en) Therapeutic peptides
JP2005502324A5 (https=)
Karim et al. Four epitopes on tumor necrosis factor-alpha defined by murine anti-tumor necrosis factor-alpha monoclonal antibodies
FI102115B (fi) Diagnostiikassa käytettävä monoklonaalinen vasta-ainekoostumus ja sitä sisältävä testipakkaus